Michael Morabito

AbbVie Inc (NYSE: ABBV)'s stock is up 51 percent year-over-year, but its lifeblood may be draining. The Rating Credit Suisse analysts Vamil Divan and Michael Morabito downgraded AbbVie to Underperform and lowered their price target from $104 to $89. The Thesis The analysts attribute AbbVie...

Credit Suisse in a note Monday listed seven catalysts for Eli Lilly and Co (NYSE: LLY) shares over the coming year even as it downgraded the shares of the company on the pretext that there are limited drivers of further upside after the stock's recent run, which lifted it by 13 percent since mid-...

Ahead of an expected uptick in news flow next month, Credit Suisse reviewed its ratings and price targets on the shares of several pharma companies, keeping in mind the fiscal year 2017 and the first-half of 2018. The firm downgraded shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:...

Credit Suisse termed the market reaction to Bristol-Myers Squibb Co (NYSE: BMY)'s CM-214 data as overly pessimistic. The comment was based on the 3-percent pullback in the company's shares in after-hours trading Tuesday. However, at the time of writing, shares of Bristol-Myers Squibb were down 1....